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The protein product of hamster islet neogenesis-associated protein (INGAP) cDNA induces new pancreatic islet development.
Manipulation of this process provides a new therapeutic strategy for the treatment of diabetes. As regulators of INGAP gene expression are
unknown over 6 kb of hamster genomic INGAP has been cloned. Sequence analysis has identified a 3 kb 5-prime region with core promoter
elements that is rich in transcription factor binding sites and six exons for the coding region. Analysis of promoter activity reveals stimulus-
responsive DNA elements which have been identified though deletion analysis. Comparison of transcription factor binding sites in INGAP to
the related gene RegIIIy exposes potential sites for differential gene regulation.
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While distinct in etiology, the two major forms of diabetes
mellitus ultimately result from a failure of the insulin-pro-
ducing pancreatic beta cell mass [1]. In type one diabetes, the
beta cells undergo autoimmune destruction [2], whereas type
two diabetes is associated with severe insulin resistance [3],
although diabetes does not ensue until there is a failure or loss
of the beta cell mass [4].
A clear rationale to address the biology of diabetes is
replacement of the destroyed or depleted beta cell mass with
new fully functional islets [5]. In recent years, numerous
islet re-population approaches have been targeted towards
this challenge. The feasibility of islet transplantation has
been proven in humans [6]. However, the practicality of this
and other exogenous islet-replacement approaches as a
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the need to induce long-term immunological tolerance
[7,8]. In a distinct approach, our group has focused on
identifying proteins or factors that ‘‘re-educate’’ the pan-
creas to produce the desired new functional beta cell mass
endogenously. One such protein has been termed INGAP or
islet neogenesis-associated protein [9].
Expression of INGAP is regulated in a pancreas-specific
manner [9]. INGAP or a bioactive peptide derived from
INGAP has been shown in animals to both initiate new islet
cell growth and reverse chemical-induced diabetes [10–12].
Since INGAP is an endogenous protein that stimulates the
production of ‘‘self’’ beta cells, therapy mediated through
INGAP is expected to bypass the immunological challenges
encountered in other re-population strategies. While the
utility of INGAP or derived peptide in human diabetes is
as yet unknown, the phenomenon of islet cell regeneration is
open to exploitation. INGAP is a factor that is detected in
the earliest stages of pancreas organogenesis [13] and its
expression in the adult pancreas appears to initiate a
primordial cascade resulting in new islet cell development
from a precursor cell population residing in the pancreatic
duct [10,12,14]. Knowledge of which pathways regulateed.
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or indeed keep INGAP turned off is vital to our ability to
exploit this cascade. The identification of the INGAP
genomic sequence including the INGAP promoter reported
here will ultimately lead to answers to these important
questions.
1.1. Genomic cloning and sequencing of the hamster
INGAP promoter region
Genomic DNAwas isolated from Syrian Golden hamster
liver and used to construct four restriction libraries which
were prepared using a universal genome walking kit [15]
(Clontech, Palo Alto, CA). The library construction and
genome walks were carried out following the manufacturers
instructions. Starting with antisense gene-specific primers
(GSPs), INGEN1_3 and INGEN2_3 (located 79–105 and
48–74, respectively, in INGAP cDNA), a series of sequen-
tial 5-prime genome walks were performed to build up the
described sequence (Fig. 1B). The sense primers were the
adapter primers (AP-1 and AP-2) supplied in the kitFig. 1. Cloning of genomic hamster INGAP has identified five introns within the
the positions of the resolved genomic fragments from genome walks (circles to a
TATA box and poly A signal are labeled as are the restriction sites (Top) used to ma
used (C) and their sequences (D) are also shown.(Clontech). Additional antisense primers for the subsequent
genome walks were designed GSPs (Fig. 1C and D). The
buffer conditions for each genome walk were optimized by
performing the PCR reaction with GC-MELT (Clontech) at
0, 0.5, 1 or 1.5 mM to allow amplification of GC-rich DNA
regions of the genomic DNA. For each genome walk, the
primary PCR was carried out using the AP-1/GSP-1 primer
pair (initial 94 jC, 1 min; 7 cycles 94 jC, 2 s, 68 jC, 3 min;
32 cycles 94 jC, 2 s, 63 jC, 3 min; 1 cycle 63 jC, 4 min).
The secondary PCR was carried out using the AP-2/GSP-2
primer pair (initial 94 jC, 1 min; 5 cycles 94 jC, 2 s, 68 jC,
3 min; 20 cycles 94 jC, 2 s, 63 jC, 3 min; 1 cycle 63 jC, 4
min). PCR amplified bands which were unique to reactions
including both sense and antisense primers were isolated
from agarose gels and column purified (Qiagen, Valencia,
CA); being either sequenced directly or subcloned into
pGEM-T (Promega, Madison, WI) before sequencing.
DNA sequencing was performed by DSSF, Iowa State
University. Six genome walks were performed each on four
different restriction libraries. Genome walk fragments
always overlapped and a 3-prime genome walk into INGAPcoding sequence (A). The genomic cloning strategy, illustrated in B, shows
rrowhead) and genomic PCR (diamond to diamond). The positions of the
ke the promoter– reporter constructs. The location in the gene of the primers
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confirmed the sequence was from the 5-prime of the INGAP
gene (Fig. 1B). Fragments obtained from the genome walks
were aligned and pieced together at overlapping regions
using sequence analysis software Omiga 2.0 (Oxford
Molecular, Burlington, MA). The resolved 5-prime region
of INGAP was analyzed for conserved promoter motifs and
transcription factor binding sites (www.Genomatix.com).
The results of these searches identified both a minimal
promoter and several binding sites for known transcription
factors. A TATA-box, CCAAT-like box and GC-rich motif
were identified in a topology consistent with mammalian
promoters. The transcriptional start site was identified to be
at position 3123 of the INGAP genomic sequence, a three-
base modification which has been previously reported [9].
Additionally, predicted binding sites for transcription factors
such as AP-1, NFnB, NFAT, STAT, MyoD and PDX are
clustered throughout the 5-prime sequence. These data
provide an invaluable point from which to determine the
transcription factors and promoter elements that are crucial
for the regulation of INGAP gene expression.
1.2. Genomic cloning of hamster INGAP coding region
To resolve the genomic sequence for the INGAP
coding region, nested genomic PCR was performed on
hamster liver genomic DNA. Sense/antisense primers
INGAP 1_1L/R and INGAP 2_1L/R (Fig. 1C and D)
were reacted in primary (1_1L/R) and secondary (2_1L/R)
PCRs using reaction conditions described above for the
genome walk. Two distinct PCR products were obtained,
the primary PCR product was approximately 2.5 kbp,
whereas the secondary PCR product was approximately
1.5 kbp suggesting the nested primers spanned an exon/
intron boundary. Sequencing of the primary and secondary
PCR products confirmed this observation and alignment
with INGAP cDNA identified the location of the exon/
intron boundaries. Resolution of the INGAP coding region
was achieved by a 3-prime genomic walk using the sense
GSPs INGEN13_5 and INGEN14_5 with adapter primers
(AP-1/AP-2), respectively. Over 6 kb of the hamster
INGAP gene has been resolved including 3 kb of the
5-prime regulatory region. Comparison of INGAP
genomic DNA with INGAP cDNA revealed six exons
generated by five intron insertions. The five introns
depicted in Fig. 1A are located at positions 3150–3426,
3508–4442, 4562–4735, 4874–5459, and 5587–5843
respectively in the INGAP genomic sequence. All splicing
sites conform to the GT/AG rule for exon/intron bounda-
ries.
1.3. INGAP promoter--galactosidase reporter deletion
constructs
To construct sequential deletions for the upstream region
of INGAP, the cloned fragments from the genome walkswere serially ligated together using enzymes unique to the
entire INGAP 5-prime region. Initially fragment 2_3 was
PCR amplified to introduce the additional restriction sites,
HindIII (3-prime) and Xba (5-prime). Using these added
restriction sites, this fragment was subcloned into the clon-
ing plasmid, pKs (Invitrogen, Carlsbad, CA). For promoter
assembly, fragments 2_3, 8_3, 14_3, 16_3 and 19_3 were
serially ligated together at the restriction sites SphI, BbsI,
PstI and AccB7I, respectively (Fig. 1B). All ligations
incorporated directional cloning; the 5-prime restriction site
in all cases was XmaI, a site originating from the AP-2
primer and therefore common to all fragments, yet unique in
the INGAP 5-prime sequence. For digestions with AccB7I
the dcm methylase-deficient E. coli INV110 (Invitrogen)
were first transformed with the cloning vectors, prior to
fragment isolation, digestion and ligation. All fragments,
once constructed, were digested with XmaI (5-prime) and
BglII (3-prime) and subcloned into pBgal-basic vector
(Clontech), a promoterless h-galactosidase expression vec-
tor. The BglII site is unique in the INGAP promoter and is
located 3-prime to the identified TATA box (Fig. 1B). The
plasmid, p2_3T, was generated by a StuI digestion of p2_3
followed by blunt-end ligation. The first ATG, start codon,
downstream of the TATA-box in the reporter gene constructs
is that for h-galactosidase. Reporter genes were sequenced
in both directions. The resulting promoter deletion reporter
constructs are illustrated in Fig. 2A.
1.4. Transient transfection assays
293T cells, a non-INGAP expressing cell line grown in
DMEM medium supplemented with 10% fetal bovine serum
(Invitrogen), were transfected with the INGAP promoter–
reporter plasmids. Per transfection, 400,000 cells in wells of
a six-well tissue culture plate were transfected with 700 ng of
a plasmid containing the INGAP promoter-h-galactosidase
reporter construct and 700 ng of pAP4 [16] (a secretory
alkaline phosphatase expression plasmid used to control for
transfection efficiency). Transfection was performed by
incubating the cells with a DNA and Lipofectamine (Invi-
trogen) mixture for 5 h at 37 jC as per manufacturers
instruction. For induction studies, transfected cells were
stimulated the day following transfection with PMA and
incubated for 2 days prior to analysis. To calculate trans-
fection efficiency, 10 Al of culture media, which had been
heat-inactivated at 70 jC for 10 min to destroy endogenous
alkaline phosphatase activity, was assayed in duplicate with
pNPP substrate buffer (Sigma, St Louis, MO) to determine
secretory alkaline phosphatase activity. Cells were harvested,
pelleted and washed with PBS, before h-galactosidase
activity was assayed using a luminescent-based h-galactosi-
dase detection kit (Clontech), following the manufacturers’
instructions. For data analysis, transfection efficiencies were
normalized using the alkaline phosphatase activity with the
normalized h-galactosidase activity being expressed as fold
increase above control transfections with pBASIC (the
Fig. 2. Identification of INGAP promoter activity. A diagram of the serially deleted INGAP promoter fragments (black line) linked to the h-galactosidase
reporter gene (hatched line) is shown (A) adjacent to the fold-induction in reporter gene activity mediated by the INGAP promoter fragments (B). Basal
intrinsic activity for the INGAP promoter fragments in unstimulated, control, cells (black bars) is compared to the corresponding activity in cells stimulated
with 50 ng/ml PMA (hatched bars). PMA induction for p14_3 is significantly higher ( P < 0.05) than that for p2_3 (t-test) data shows means and S.E. (n= 8).
Electrophoretic mobility shift analysis of a fluorescine-labeled probe from INGAP fragment 2_3T is shown in (C). A specific shifted band (arrow) is detected
(lanes 2 and 5) following incubation of the fluo-probe with nuclear extracts from control (lane 2 and 3) or PMA stimulated (lane 5 and 6) cells. No band is
detected in samples containing fluo-probe in the absence nuclear extract (lanes 1 and 4) or samples containing fluo-probe, nuclear extract and a 25-fold excess
of unlabelled probe (lanes 3 and 6). The response of promoter fragments to increasing doses of PMA is shown in (D).
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had undergone equivalent stimulation.
The data in Fig. 2B shows that the INGAP promoter
in 293T cells has low constitutive activity. This basal
activity can be elevated by the addition of PMA, a
phorbol ester which enhances transcription factor activity
by stimulating intracellular signaling cascades, principally
PKC and Raf [17]. The response to PMA is bimodal
being detected in all INGAP promoter deletions tested
and peaking in the p14_3 INGAP promoter fragment that
contains the region 1769–3134 of the INGAP genomic
sequence. These data both confirm promoter activity
associated with the INGAP 5-prime sequence and reveal
that the promoter is subject to at least two PMA-sensitive
DNA elements, one located proximal to the minimal
promoter and one located within 1769–2168 of the
INGAP genomic sequence. Extension of the 5-prime
region indicates that a possible negative regulatory
DNA element neutralizes the activity of the PMA-respon-
sive region located 1769–2168 of the INGAP genomic
sequence. The response of the INGAP promoter to PMA
occurs at a dose of PMA that is physiologically relevant
[17]. Moreover, the promoter response to PMA is dose-
dependent plateauing near 100 ng/ml with an EC50 of
approximately 17 ng/ml. Increasing the dose of PMA up
to 300 ng/ml did not overcome the inhibitory effects of
the DNA elements located in the 5-prime of p19_3 (Fig.
2C), region 1–1400 in the INGAP genomic sequence.
Many mammalian promoters require occupation of sev-
eral transcriptionally active DNA elements for optimal gene
expression in vivo/in vitro. For example, the loss of onetranscriptionally active site in the interleukin-2 promoter
severely reduces the level of IL-2 gene transcription [18].
The role of a negative DNA element(s) located within 1–
1400 of the INGAP genomic sequence could be critical to
regulating the tissue-specific expression of INGAP. Pre-
vious reports have shown INGAP expression can be
induced in the exocrine pancreas in vivo [9]. It is therefore
anticipated that other pancreatic exocrine-specific transcrip-
tion factors are likely to be involved in regulating INGAP
expression. These speculations will be strengthened through
transfections of the INGAP promoter–reporter constructs
into exocrine cells or cell lines which endogenously express
INGAP. To date, transfection studies with the amphocrine
rat pancreatic cell line AR42J have not demonstrated
increased constitutive activity. Since this is a tumor-derived
cell line, it is possible that the cells may either be inappro-
priate candidates for INGAP expression or in the wrong
transition state; these cells have the capacity to differentiate
in a stimulus-dependent manner into neuroendocrine-like or
exocrine-like cells [19]. Supporting this contention, INGAP
mRNA was not detected in these cells (data not shown).
In support of the observations for a physiologically
functional DNA enhancer element located proximal to the
transcriptional start site of INGAP, fluorescent oligonucleo-
tides from 2_3T, region 2931–3134 of the INGAP genomic
sequence, were evaluated in an electrophoretic mobility shift
assay [20] when incubated with nuclear extracts from 293T
cells stimulated with and without PMA. A specific shifted
band, as determined by its displacement in the presence of a
25-fold excess of unlabeled probe, was observed in both
nuclear extracts. Currently, we are mapping the actual
Fig. 3. Comparison of the regulatory regions of INGAP and RegIIIy. Sequence alignment of the 5-prime regions of the two genes are shown in A, where areas of sequence identity are shaded. Regions for
DNA insertions in RegIIIy (open line), INGAP (closed line) and the position of the TATA-box (checkered line) are marked. AP-1 binding sites in INGAP are outlined. The exocrine enhancer consensus-motifs
present in RegIIIy (hashed lines) and the equivalent region in INGAP is boxed for both genes. The locations of predicted transcription factor binding sites for RegIIIy and INGAP are compared in B. Sites on
the sense strand (up triangles) and antisense strand (down triangles) were predicted using default vertebrate settings for MatInspector Professional (www.Genomatix.com). The positions of predicted binding
sites for the transcription factors AP-1 (A), NFnB (R), NFAT (N), STAT (S), MyoD (D) and PDX (P) are shown, for reference, the CAAT-like box (C) and TATA-box (T) are also marked.
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1769–2168 regions of the INGAP genomic sequence to
reveal the origins of the PMA response. In summary, we
report here the genomic sequence of hamster INGAP
including initial analysis of the 5-prime regulatory region.
These data confirm the identification of the INGAP pro-
moter through the presence of transcriptionally active,
stimulus-responsive DNA elements proximal to the tran-
scriptional start of INGAP.
Resolution of the INGAP gene has identified the coding
region of INGAP to consist of six exons spanning approx-
imately 3 kb of genomic sequence (Fig. 1A). This organ-
ization is analogous to the related gene family of Reg
proteins. Reg-related proteins are a group of homologous
calcium dependent (C-type) lectins [21] that have been
classified into four sub-types based upon structural similar-
ities [22,27]. INGAP is a C-type lectin whose structural
features are consistent with a type III Reg-related protein.
The genomic organization and protein structure of
INGAP has the greatest homology to mouse RegIIIy
(72.2% similarity in amino acid sequence). The biological
function of RegIIIy has not been defined and while
expressed in the pancreas, the expression of RegIIIy in
other organs is ambiguous. Abe et al. [23] report the
expression of RegIIIy to be restricted to the pancreas but a
parallel report of a mouse protein termed INGAPrP whose
cDNA is identical to RegIIIy, describe a broader tissue
expression of RegIIIy which includes pancreas, stomach,
duodenum and skeletal muscle [24]. This broad tissue
expression is distinct to that reported for INGAP which is
restricted to the pancreas and pancreas/duodenal border [9].
Furthermore, while the actual tissue expression profile of
mouse RegIIIy remains to be resolved, both reports describe
the constitutive expression of RegIIIy in the pancreas. This
is distinct to the expression reported for INGAP in the
hamster pancreas which was not detected in the normal
(unwrapped) pancreas [9]. It is difficult to conclude whether
INGAP and RegIIIy are orthologs. Conceivably, the dispar-
ity in expression may reflect different genes or species
differences in the regulation of the same gene. A detailed
analysis of the promoter for INGAP and the consequent
regulation of INGAP expression is expected to resolve how
expression of the two genes are differentially regulated.
There is a 60% sequence similarity between the reported 5-
prime region of RegIIIy [23] and the equivalent region of
the INGAP promoter (Fig. 3A); however, analysis of the
two promoter regions (MatInspector professional and Ali-
baba2.1; www.Genomatix.com) reveals a disparate distribu-
tion of predicted transcription factor binding sites. Of the
predicted DNA binding sites for RegIIIy and INGAP (109
and 139 respectively) only 12 transcription factor binding
sites were identified to have an analogous location in the
two promoters and several of the binding sites are unique to
one of the two promoters (Fig. 3B). Sequence alignment
suggests several regions of DNA insertions between INGAP
and RegIIIy, which in INGAP, correspond to consensusrecognition sequences for additional transcription factor
binding sites. Moreover, the region of the RegIIIy promoter
that contains the dual motif pancreatic exocrine enhancer
[25,26] is not present in the INGAP promoter. The equiv-
alent region in the INGAP promoter only has one of these
motifs (Fig. 3A). Based upon the distinct patterns for
predicted transcription factor binding sites, it would appear
feasible that the regulation of INGAP and RegIIIy is
distinct, further analysis will reveal the significance of the
differences noted here.
Regulation of INGAP presents a new approach to stim-
ulating the endogenous production of islets as a therapeutic
rational for treating diabetes. Identification of the INGAP
promoter reported here is an important achievement towards
defining the cascade of factors that regulate islet neogenesis.Acknowledgements
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